期刊文献+

腹腔热灌注化疗对妇科癌性腹水的疗效观察 被引量:3

Clinical study of intraperitoneal hyperthermic perfusion chemotherapy in the treatment of gynecological malignant seroperitoneum
下载PDF
导出
摘要 目的:评价腹腔热灌注化疗对妇科癌性腹水治疗的临床价值。方法:对49例晚期妇科恶性肿瘤合并癌性腹水患者,使用深静脉软管经皮腹腔内置管,经体外循环热灌注治疗后,注入顺铂,观察恶性腹水量的变化。同时检测腹水中的相关肿瘤标志物的变化情况。观察患者一般生活体力状况变化及生活质量情况。结果:行腹腔热灌注化疗后,11例患者腹水减少程度>90%,28例患者腹水减少程度>50%,总有效率79.59%。18.36%的患者发生恶心及呕吐等症状。治疗后患者一般生活状况评分、腹水最大直径等指标较治疗前好转(P<0.01),肿瘤标志物水平均明显低于治疗前(P<0.05)。结论:腹腔热灌注化疗治疗妇科癌性腹水近期疗效好且安全,副作用小,患者耐受性好,是恶性腹水患者较可靠的治疗措施。 Objective:To explore the effects and side effects of intraperitoneal hyperthermal chemotherapy in the treatment of malignant seroperitoneum in gynecology carcinoma. Methods: Total of 49 cases diagnosed as gynecology carcinoma with malignant seroperitoneum, received intraperitoneal hyperthermal chemotherapy combining with DDP. To observe the change in volume of seroperitoneum, and test tumor markers ( CEA, CA125, CA242, CA199, CA153 ). Results:After the treatment, the degree of reduction in the amount of seroperitoneum was greater than 90% in 11 ca- ses ,greater than 50% in 28 cases. The total effective rate was 79.59%. 18.36% of the patients had side effects such as nausea and vomiting. The PS score and maximum diameter of seroperitoneum of the patients after treatment were improved significantly( P 〈 0.01 ). Tumor markers were significantly lower than before treatment( P 〈 0.05 ). Con- clusion:Intraperitoneal hyperthermal chemotherapy in the treatment of gynecological malignant seroperitoneum is ef- fective, safe and tolerable with slight side effects.
作者 余敏 张岩
出处 《现代肿瘤医学》 CAS 2013年第10期2303-2305,共3页 Journal of Modern Oncology
基金 陕西省卫生厅科研基金项目资助(编号:2012D85)
关键词 热灌注治疗 癌性腹水 肿瘤标志物 顺铂 intraperitoneal hyperthermal chemotherapy malignant seroperitoneum tumor markers Cisplatin
  • 相关文献

参考文献14

二级参考文献123

共引文献256

同被引文献32

  • 1汪志霞,韩克,谈勇.天然药物有效成分及其制剂治疗妇科肿瘤的研究进展[J].国外医学(中医中药分册),2005,27(2):90-94. 被引量:2
  • 2Lemieux J, Goodwin PJ, Bordeleau LJ, et al. Quality - of - life measurement in randomized clinical trials in breast cancer:An up- dated systematic review (2001 - 2009) [ J ]. J National Cancer In- stitute,2011,103 ( 3 ) : 178 - 231.
  • 3Saada E, Follana P, Peyrade F, et al. Pathogenesis and management of refractory malignant ascites [ J ]. Bull Cancer, 2011,98 ( 6 ) : 679 - 687.
  • 4Schwartz RN, Eng KJ, Frieze DA, et al. NCCN task force report : Specialty pharmacy[J]. J Natl Compr Canc Netw,2010,8 ( Suppl 4) :S1 - 12.
  • 5Vantard N, Ranchon F, Schwiertz V, et al. EPICC study tion of pharmaceutical intervention in cancer care [ J ] Pharm Ther,2015,40 (2) : 196 - 203.
  • 6Evalua- J Clin Caracuel F, Bafios fl, Herrera MD, et al. Influence of pharmaceuti- cal care on the delayed emesis associated with chemotherapy[ J]. Int J Clin Pharm,2014,36(2) :287 -290.
  • 7Fujii H, Iihara H, Ishihara M, et al. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with coloreetal cancer receiving chemotherapy of moderate emetic risk [J]. Antieancer Res, 2013,33 ( 12 ) : 5549 - 5556.
  • 8Nakamura F, Higashi T. Pattern of prophylaxis administration for chemotherapy - induced nausea and vomiting: An analysis of city -based health insurance data [ J]. Int J Clin Oncol, 2013, lg (6) :971 -976.
  • 9Aapm MS, Schmoll HJ, Jahn F, et al. Review of the efficacy of aprepitant for the prevention of chemotherapy - induced nausea and vomiting in a range of tumor types[ J]. Cancer Treatment Re- views,2013,39 ( 1 ) :113 - 117.
  • 10Nazer LH, Hawari F, A1 Najjar T. Adverse drug events in critically ill patients with cancer : Incidence, characteristics, and outcomes [J]. J Pharm Praet,2014,27(2) :208 -213.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部